"Neoplasm Grading" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
| Descriptor ID |
D060787
|
| MeSH Number(s) |
E01.789.612
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Grading".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Grading".
This graph shows the total number of publications written about "Neoplasm Grading" by people in this website by year, and whether "Neoplasm Grading" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 38 | 38 |
| 2012 | 1 | 64 | 65 |
| 2013 | 2 | 81 | 83 |
| 2014 | 2 | 70 | 72 |
| 2015 | 2 | 88 | 90 |
| 2016 | 2 | 69 | 71 |
| 2017 | 1 | 63 | 64 |
| 2018 | 0 | 54 | 54 |
| 2019 | 2 | 64 | 66 |
| 2020 | 5 | 51 | 56 |
| 2021 | 2 | 33 | 35 |
| 2022 | 0 | 9 | 9 |
| 2023 | 1 | 5 | 6 |
| 2024 | 6 | 13 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Grading" by people in Profiles.
-
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol. 2024 Oct 03; 26(10):1805-1822.
-
Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition. Arch Pathol Lab Med. 2024 Oct 01; 148(10):1119-1125.
-
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. ESMO Open. 2024 Sep; 9(9):103689.
-
Sex-Specific Differences in Patients with IDH1-Wild-Type Grade 4 Glioma in the ReSPOND Consortium. AJNR Am J Neuroradiol. 2024 Sep 09; 45(9):1299-1307.
-
Quality of life and survivorship in patients with low-grade ovarian cancer. Gynecol Oncol. 2024 Nov; 190:96-103.
-
The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists' Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey-Based Study. AJR Am J Roentgenol. 2024 Oct; 223(4):e2431595.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
-
Impact of Cutaneous Squamous Cell Carcinoma Histologic Features on Percent Interrater Agreement Regarding Tumor Differentiation. Dermatol Surg. 2024 Nov 01; 50(11):1007-1009.
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29; 403(10446):2807-2817.
-
Recurrent low-grade uterine sarcoma: a diagnostic and therapeutic challenge. Int J Gynecol Cancer. 2024 Jun 03; 34(6):946-950.